NCT00353418View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection

PHASE4CompletedINTERVENTIONAL
Enrollment

415

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Peginterferon alfa-2a

180 µg subcutaneously weekly for 48 weeks

DRUG

Ribavirin

800 mg orally daily for 48 weeks

DRUG

Ribavirin

1000 mg or 1200 mg (based on patient weight of \< 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00353418 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection | Biotech Hunter | Biotech Hunter